Literature DB >> 31790880

Tetra-cationic platinum(II) porphyrins like a candidate photosensitizers to bind, selective and drug delivery for metastatic melanoma.

Gabriela Klein Couto1, Bruna Silveira Pacheco1, Victoria Mascarenhas Borba1, João Carlos Rodrigues Junior1, Thaís Larré Oliveira1, Natália Vieira Segatto1, Fabiana Kommling Seixas1, Thiago V Acunha2, Bernardo Almeida Iglesias3, Tiago Collares4.   

Abstract

Photodynamic therapy (PDT) is an expanding treatment modality due to its minimally invasive localized activity and few adverse effects. This therapy requires photosensitive compounds, which have high sensitivity to light exposure. Thus, in this work, the in vitro antitumor activity of meso-tetra(3- and 4-pyridyl)porphyrins (3-TPyP and 4-TPyP) in metastatic melanoma cell (WM1366 line) and non-tumoral Ovarian lineage Chinese Hamister (CHO) was evaluated using photodynamic process. Cell viability tests, molecular docking, annexin V, confocal microscopy and qRT-PCR were performed. Our results show that both porphyrins inhibited the viability of metastatic melanoma cells when exposed to light and did not alter viability in the dark. In addition, they did not demonstrate cytotoxicity in non-tumor cells. Molecular coupling demonstrated platinum porphyrin affinity for the N-terminal region of APO B-100, LDL receptor, and therefore of the cells under study. Genes such as Caspase 3 and 9, P21, Bax / BCL2, MnSod and GSH showed increased expression. For meta isomer 3-PtTPyP treatment, caspase-9 and caspase-3 expression levels showed a 4.89 and 3.23-fold increase, respectively, while for the para isomer 4-PtTPyP, this change was 3.77 and 12.16-fold, respectively. We also observed an upregulated expression of p21, a protein well-known by its action in cell cycle arrest in a p53-dependent manner.
Conclusion: 3-PtTPyP and 4-PtTPyP demonstrated antitumor effect on WM1366 cells, inducing apoptosis and significant alteration of cell cytoskeleton actin. Our work shows that platinum(II) porphyrins may be promising photosensitizers for the treatment of metastatic melanoma by PDT.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  APO B-100, Cancer; LDL receptor; Molecular docking; Photosensitizer; Platinum(II) porphyrins

Mesh:

Substances:

Year:  2019        PMID: 31790880     DOI: 10.1016/j.jphotobiol.2019.111725

Source DB:  PubMed          Journal:  J Photochem Photobiol B        ISSN: 1011-1344            Impact factor:   6.252


  4 in total

Review 1.  The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval.

Authors:  Mariana Matias; Jacinta O Pinho; Maria João Penetra; Gonçalo Campos; Catarina Pinto Reis; Maria Manuela Gaspar
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

2.  Novel meso-substituted porphyrin derivatives and its potential use in photodynamic therapy of cancer.

Authors:  Pablo Vallecorsa; Gabriela Di Venosa; M Belén Ballatore; Dario Ferreyra; Leandro Mamone; Daniel Sáenz; Gustavo Calvo; Edgardo Durantini; Adriana Casas
Journal:  BMC Cancer       Date:  2021-05-13       Impact factor: 4.430

3.  Evaluation of the correlation between porphyrin accumulation in cancer cells and functional positions for application as a drug carrier.

Authors:  Koshi Nishida; Toshifumi Tojo; Takeshi Kondo; Makoto Yuasa
Journal:  Sci Rep       Date:  2021-01-21       Impact factor: 4.379

Review 4.  Monofunctional Platinum(II) Anticancer Agents.

Authors:  Suxing Jin; Yan Guo; Zijian Guo; Xiaoyong Wang
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.